Microbiome - October 2020

Microbiome - October 2020

$275 million finding raised by microbiome players in September 2020

20 Oct 2020

  • Finch Therapeutics raised $90 million Series D financing to advance its pipeline of oral microbiome drugs, from multiple investors including Baupost Group, Humboldt Fund, MSD Capital, MSD Partners, Octave Group, and OMX Ventures, along with support from existing investors, including Avenir Growth Capital, OCV Partners, Shumway Capital, SIG, SymBiosis, TPTF, and Willett Advisors
  • Followed by Vedanta Biosciences with award of up to $76.9 million including $7.4 Million upfront from BARDA to advance the development of VE303 for CDI
  • 4 out 6 companies are based in the United states

 

Data – Secondary research

Home